Table D-12. Evidence table for studies addressing management of PPH (Zatta 2014)

| **Study**  **Description** | **Intervention** | **Inclusion/Exclusion**  **Criteria & Population** | **Outcomes** |
| --- | --- | --- | --- |
| **Author:**  Zatta et al.,  201415  **Country:**  Australia and New Zealand  **Enrollment period:**  2000 to 2009  **Birth setting:**  NR  **Facility characteristics:**  96 hospitals d, 75 reported off-label use of rFVIIa  **Funding:**  Unrestricted educational grant from Novo Nordisk Pharmaceuticals (makers of rFVIIa)  **Design:**  Registry- case series | **Intervention:**  Received rFVIIa for off-label indication- subset of registry cases who received it for obstetric hemorrhage  **Groups:**  **G1:** intervention  **N: 3446 cases of off-label use of rFVIIa, 177 obstetric cases**  **G1:** 175 patients (177 cases)  **Duration of treatment:** NR  **Timing of treatment:** NR  **Order of treatment:** NR  **Length of follow-up:**  up to 28 days following rFVIIa administration | **Operational definition of PPH:** NR  **Definition of success of treatment:** NR  **Method of blood loss measurement:** NR  **Severity:** NR  **Inclusion criteria:**  Registry patients receiving rFVIIa to preempt or treat clinical bleeding episodes outside the approved indications  criterion 2  **Exclusion criteria:**  patients with acquired hemophilia  **Maternal age, yrs, mean ± SD:** NR  **Parity, n:** NR  **Weeks gestation, n (%):** NR  **Single pregnancy, n (%):** NR  **Multiple pregnancy, n (%):** NR  **Race/ethnicity:** NR  **BMI:** NR  **Baseline hemoglobin:** NR  **SES:** NR  **Mode of birth, n:** NR  **Risk factors, n (%):** NR  **Primary etiology of PPH, n (%):**  Atony  **G1:** 39  Placenta previa  **G1:** 46  Placenta accreta/percreta  **G1:** 30  Intrauterine fetal death  **G1:** 23  Preeclampsia/Eclampsia  **G1:** 20  Placental abruption  **G1:** 17  Other  **G1:** 2 | **Harms pre-specified:** 28-day mortality  **Harms, n (%):**  28-day mortality **G1:** 11 (6)  Total with thromboembolic adverse events  **G1:** 15 (8.6)  Arterial thrombosis  **G1:** 2 (1.1)  Cerebrovascular accident  **G1:** 1 (0.6)  Acute myocardial infarction  **G1:** 1 (0.6)  Venous thrombosis  **G1:** 5 (2.9)  Deep vein thrombosis  **G1:** 1 (0.6)  Pulmonary embolism  **G1:** 1 (0.6)  Other thrombosis  **G1:** 3 (1.7)  Patients with DIC  **G1:** 9 (5.1)  Stroke  **G1:** 0 (0) |